[{"x_label":"Neuroblastoma  (Dataset = All Cohorts, Specimen = Pediatric Relapse Tumors, N = 13)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":13,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"All Cohorts","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":44.65,"TPM_sd":44.74,"TPM_min":0.3,"TPM_25th_percentile":13.26,"TPM_median":34.36,"TPM_75th_percentile":53.22,"TPM_max":141.13},{"x_label":"Neuroblastoma  (Dataset = PBTA, Specimen = Pediatric Relapse Tumors, N = 5)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":5,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":10.75,"TPM_sd":11.68,"TPM_min":0.3,"TPM_25th_percentile":0.92,"TPM_median":6.83,"TPM_75th_percentile":18.84,"TPM_max":26.85},{"x_label":"Neuroblastoma  (Dataset = TARGET, Specimen = Pediatric Relapse Tumors, N = 8)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":8,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TARGET","Disease":"Neuroblastoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000621","MONDO":"MONDO_0005072","GTEx_tissue_subgroup_UBERON":"","TPM_mean":65.84,"TPM_sd":44.94,"TPM_min":13.26,"TPM_25th_percentile":38.32,"TPM_median":48.88,"TPM_75th_percentile":88.86,"TPM_max":141.13},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 13)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":13,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":13.75,"TPM_sd":19.3,"TPM_min":1.2,"TPM_25th_percentile":2.4,"TPM_median":4.01,"TPM_75th_percentile":17.67,"TPM_max":69.9},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 14)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":26.71,"TPM_sd":16.68,"TPM_min":4.4,"TPM_25th_percentile":13.83,"TPM_median":27.83,"TPM_75th_percentile":33.23,"TPM_max":58.78},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 5)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":5,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":2.07,"TPM_sd":2.47,"TPM_min":0.08,"TPM_25th_percentile":0.37,"TPM_median":1.25,"TPM_75th_percentile":2.47,"TPM_max":6.16},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 3)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":3,"Gene_Ensembl_ID":"ENSG00000213420","Gene_symbol":"GPC2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.74,"TPM_sd":1.13,"TPM_min":1.02,"TPM_25th_percentile":1.08,"TPM_median":1.15,"TPM_75th_percentile":2.09,"TPM_max":3.04}]